Advancing Precision RNA Therapeutics for Hurler Syndrome (MPS-1H)
Dawn Therapeutics is building a dual-platform delivery and manufacturing strategy to address key barriers in rare disease treatment: cost, tissue targeting, and scalability. With an initial focus on Hurler syndrome (MPS-1H), our technologies are designed to support precise delivery to affected tissues, including CNS and musculoskeletal compartments, while creating a platform foundation for broader future applications in rare genetic and neurological disorders.
Disease Area Tiles
Hurler Syndrome (MPS I H)
Lead preclinical programme focused on IDUA replacement in Hurler syndrome (MPS I-H), supported by a stealth lentiviral approach and complementary targeted delivery platform data in CNS and musculoskeletal tissues.
A scientific success story built around DAWN-01
Dawn Therapeutics is advancing DAWN-01 as a focused preclinical programme for Hurler syndrome (MPS I-H), using a platform-led development strategy designed to improve delivery precision and accelerate translational progress. This page summarises the scientific rationale, disease-specific preclinical evidence, and the broader delivery platform results that support the programme’s long-term potential.
Hurler syndrome remains a high-priority disease area because current treatment pathways improve outcomes, but many patients continue to experience substantial long-term multisystem burden, especially in hard-to-treat tissues. DAWN-01 is positioned as a lead programme in a disease setting with clear unmet need and strong translational relevance.
Why Hurler syndrome is the right first programme
Hurler syndrome (MPS I-H) is a severe lysosomal storage disorder caused by deficiency of alpha-L-iduronidase (IDUA), resulting in glycosaminoglycan (GAG) accumulation and progressive multisystem disease. Current disease-modifying care, especially early HSCT and adjunctive ERT, has improved survival and important clinical outcomes, but residual disease burden often persists across multiple tissues. This makes Hurler syndrome a strong first indication for a precision delivery strategy with translational platform value beyond a single programme.
Dawn positioning: DAWN-01 is framed as a focused preclinical Hurler programme while the underlying delivery platform is being built for broader use across rare disease, CNS, and musculoskeletal indications.
Clinical reality today
HSCT remains the standard disease-modifying pathway for severe Hurler syndrome, often alongside ERT and multidisciplinary specialist care. Early treatment is critical, but long-term morbidity can remain significant.
Why further innovation matters
Even with best current care, many patients continue to live with residual multisystem complications, including skeletal and other hard-to-correct manifestations. This is where improved tissue delivery could have major clinical value.
Platform fit
Hurler syndrome is well suited to a platform-led development model because it is biologically measurable (IDUA and GAG markers) and clinically challenging across multiple organs and tissues.
DAWN-01 and platform evidence: the preclinical success story
Dawn’s Hurler programme is supported by two layers of evidence from the business plan: disease-specific DAWN-01 preclinical proof-of-concept in MPS1H models, and broader in vivo performance data from the targeted iLNP platform that demonstrates delivery strength across joint, cartilage, and CNS-relevant contexts.
Disease model proof-of-concept
Preclinical studies in MPS1H mice reported biomarker improvement, including normalisation of urinary GAG-related disease markers in treated animals. Dawn’s materials also describe no major early safety red flags in wild-type mice and a scalable vector manufacturing process established for translational development.
Increase IDUA & Reduced GAGs
The recent research at Dawn Therapeutics reports significant increases in IDUA activity and broad tissue-level GAG reductions in preclinical models, including a mean reduction in heparan sulfate disaccharides and normalisation of urinary GAGs in treated animals.
Delivery Signal (platform evidence)
Dawn’s platform materials report strong BBB-related delivery performance in TfR-targeting datasets, including high brain exposure ratios in animal studies. A related peer-reviewed TfR-targeting conjugate study involving Dawn-linked authors also reports high brain-to-serum ratios and neuronal localisation in mice, supporting the broader CNS delivery rationale.
Joint tissue expression gain
Targeted LNPs with joint-targeting antibodies reportedly increased gene expression about 7-fold in joint tissues in vivo.
Joint NOTCH1 knockdown
An siRNA-loaded targeted LNP version reportedly achieved about 5-fold knockdown of NOTCH1 in joints in animal data.
Brain-to-plasma exposure ratio
Dawn reports a brain-to-plasma concentration ratio of 8.5:1 in animal models, supporting BBB-penetrant delivery capability.
How the platform supports a Hurler-focused strategy
1. Tissue-targeting performance matches the disease challenge
Hurler syndrome is not a single-organ condition. It affects the brain, skeleton, joints, airway, heart, and other systems. Dawn’s platform story is strongest where conventional delivery has historically struggled, especially cartilage, joint tissues, and CNS access. The reported in vivo cartilage transgene expression and joint delivery data are directly relevant to this disease biology.
2. Modality flexibility supports programme design
Dawn describes the iLNP platform as adaptable across replacement genes, mRNA, siRNA, and even CRISPR-related cargo types. For a Hurler-first programme, this gives the company scientific flexibility to optimise payload strategy over time while preserving the same delivery architecture and development learning.
3. DAWN-01 is a lead programme, not a one-off project
The business plan positions DAWN-01 as the first focused programme in a broader platform company. This is important scientifically because the lessons from Hurler disease development, including biodistribution, biomarker strategy, toxicology, and CMC, can strengthen future programmes in metabolic, musculoskeletal, and CNS indications.
4. A credible translational path is already defined
Dawn’s development plan is structured around staged non-clinical work, manufacturing transfer, toxicology, regulatory interactions, and CTA/IND-readiness milestones. That milestone discipline is a strong feature of the story because it keeps the Hurler programme technically focused and decision-driven.
DAWN-01 translational pathway (preclinical to CTA/IND-readiness)
The business plan outlines a staged 24-month path to regulatory filing readiness for the Hurler programme, including manufacturing transfer, dose-range finding, toxicology, and MHRA scientific advice preparation.
Set up GMP manufacturing for DTX-101, including technology transfer and pilot batch production.
Conduct dose-range finding and single-dose acute toxicology studies in rodents.
Launch a 6-month GLP toxicology study in rodents to evaluate longer-term safety.
Engage with the MHRA for scientific advice and refine the first-in-human trial strategy.
Finalise CTA/IND submission preparation, including preclinical package, CMC documentation, and protocol planning.
Decision discipline: The plan includes formal Go/No-Go gates during the preclinical package, which helps keep DAWN-01 development rigorous and resource-efficient.
Scientific and clinical background resources
For clinicians, researchers, and partners who want deeper background on Hurler syndrome (MPS I-H), the following pages on our sister website provide useful scientific context and current care information.
Hurler syndrome research overview
Broad scientific context, unmet need, and why research remains important despite progress in current care.
Rationale for systemic advanced therapy approaches
Background on residual disease burden after HSCT and ERT and the rationale for better tissue-wide enzyme delivery.
HSCT and ERT guidance
Clinician-focused summary of current disease-modifying treatment roles, timing, and multidisciplinary coordination.
Current treatments overview
Structured review of HSCT, ERT, and supportive care, including what each approach can and cannot address.
